公司代码：603301 公司简称：振德医疗 2022 年半年度报告 振德医疗用品股份有限公司 2022 年半年度报告 1 / 159 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人鲁建国、主管会计工作负责人金海萍及会计机构负责人（会计主管人员）马淑燕 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2022年中期不进行利润分配或资本公积金转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提 ...

2022 年第一季度报告 单位：元 币种：人民币 证券代码：603301 证券简称：振德医疗 振德医疗用品股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|------------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期 增减变动幅度 (%) | | 营业收入 | 1,264,804,817.5 ...

2021 年年度报告 公司代码：603301 公司简称：振德医疗 振德医疗用品股份有限公司 2021 年年度报告 1 / 216 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人鲁建国、主管会计工作负责人金海萍及会计机构负责人（会计主管人员）马淑燕 声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 2021年度利润分配预案：公司拟以利润分配股权登记日总股本为基数，向全体股东每10股派 发现金股利6.00元（含税），合计分配现金股利136,322,841.60元（含税），剩余未分配利润结 转至下年度。本次利润分配不送红股，不以资本公积金转增股本。在利润分配预案公布后至利润 分配股权登记日期间，若公司总股本发生变动，公司拟维持每股分配比例不变，按照利润分配股 权登记日总股本为 ...

2021 年第三季度报告 单位：元 币种：人民币 1 / 15 证券代码：603301 证券简称：振德医疗 振德医疗用品股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|--------------------------------------|------------------|--------------- ...

2021 年半年度报告 公司代码：603301 公司简称：振德医疗 振德医疗用品股份有限公司 2021 年半年度报告 1 / 158 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人鲁建国、主管会计工作负责人金海萍及会计机构负责人（会计主管人员）马淑燕 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2021年中期不进行利润分配或资本公积金转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 本 ...

2021 年第一季度报告 公司代码：603301 公司简称：振德医疗 振德医疗用品股份有限公司 2021 年第一季度报告 1 / 26 2021 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 26 2021 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人鲁建国、主管会计工作负责人金海萍及会计机构负责人（会计主管人员）马淑燕 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | --- | |-------------------------------------------------|------- ...

Dividend and Share Capital - The company plans to distribute a cash dividend of 23.00 CNY per 10 shares (including tax), totaling approximately 517.74 million CNY based on 225,104,736 shares after excluding repurchased shares[8]. - The company reported a total share capital of 227,204,736 shares as of the report date, with 2,100,000 shares held in the repurchase account not participating in the dividend distribution[8]. - The company's net profit attributable to ordinary shareholders for 2020 was RMB 2,549,453,200.21, with a dividend payout ratio of 20.31%[179]. - The cash dividend policy aims to provide continuous and stable cash dividends while ensuring the company's operational growth[176]. - The company completed its share repurchase ahead of schedule due to business needs and operational conditions[174]. - The company repurchased a total of 2,100,000 shares, accounting for 0.92% of the total share capital, with a total transaction amount of RMB 133,344,319.82[174]. Financial Performance - The company's operating revenue for 2020 reached ¥10,398,545,638.73, a significant increase of 456.75% compared to ¥1,867,727,915.16 in 2019[29]. - Net profit attributable to shareholders was ¥2,549,453,200.21, up 1,524.99% from ¥156,890,061.60 in the previous year[29]. - The net cash flow from operating activities increased to ¥3,120,839,894.43, representing a growth of 1,478.07% compared to ¥197,762,736.75 in 2019[29]. - Basic earnings per share rose to ¥12.50, a 1,462.50% increase from ¥0.80 in 2019[29]. - The weighted average return on equity increased to 94.88%, up 81.6 percentage points from 13.28% in 2019[29]. - The company's net assets attributable to shareholders grew to ¥4,182,785,620.66, a 207.83% increase from ¥1,358,786,069.59 at the end of 2019[29]. - Total assets increased to ¥6,400,086,700.05, reflecting a growth of 139.77% compared to ¥2,669,238,311.75 in 2019[29]. Risk Management and Compliance - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[10]. - The company has not violated decision-making procedures for external guarantees[10]. - The company has maintained the accuracy and completeness of the annual report as confirmed by its board of directors and management[5]. - The company has not reported any instances of more than half of the directors being unable to guarantee the authenticity of the annual report[10]. - The company emphasizes that forward-looking statements in the report do not constitute a substantive commitment to investors, highlighting potential investment risks[9]. - The company has detailed potential risks in the "Discussion and Analysis of Operating Conditions" section of the report[12]. Market and Sales Strategy - The increase in revenue was primarily driven by a surge in sales of pandemic-related protective products and the consolidation of Rocialle Healthcare Limited's financials following the acquisition of a 55% stake[30]. - The company has established a marketing network covering over 5,300 hospitals in China, including more than 800 top-tier hospitals[43]. - The company has a 95% coverage rate in the top 100 chain pharmacies across the country, totaling over 70,000 pharmacy stores[43]. - The company operates over 10 online stores on platforms like Tmall, JD, and Pinduoduo, with a total fan base exceeding 5 million[43]. - The company ranks among the top three in China's medical dressing exports for several consecutive years[43]. Research and Development - The company has invested a total of ¥40,052.70 million from its IPO proceeds into fundraising projects, ensuring production capacity for its wound care and surgical infection control products[89]. - Research and development expenses surged by 409.70% to ¥259,712,735.22, up from ¥50,953,817.91 in the previous year[91]. - The company is focusing on enhancing its R&D capabilities, with several projects in clinical trials and product registration stages, including a dermal substitute and a skin cell enrichment device[135]. - The company has recognized the need for continuous improvement in its supply chain and quality management systems to mitigate product quality risks[167]. Acquisitions and Investments - The company acquired 70% equity of Suzhou Medis for a total transaction amount of CNY 104.16 million, with payments of CNY 62.50 million made in early 2019 and CNY 20.83 million during the reporting period[141]. - The company invested CNY 30 million to subscribe for additional capital of CNY 3.15 million in Stanger, acquiring a total of 60% equity after a cash purchase of CNY 45 million[141]. - The company acquired 65% equity of Hangzhou Xindong for CNY 1.95 million, completing the registration procedures during the reporting period[141]. - The company approved an investment of approximately CNY 360 million for the relocation and expansion of production lines for wound care products and surgical control products, with partial completion by the end of the reporting period[142]. Operational Efficiency - The company implemented lean manufacturing and smart factory initiatives to enhance operational efficiency and supply chain responsiveness[81]. - The company aims to strengthen its strategic partnerships with international and regional clients to further develop new product lines and increase market share[158]. - The company plans to gradually reduce shareholdings after the lock-up period, with annual reductions not exceeding 5% of the total share capital at the end of the previous year[191]. Future Outlook - The company aims to become a leading healthcare enterprise with a market value of over 100 billion RMB by focusing on "medical + health" sectors and enhancing digital operations and continuous R&D[154]. - The company plans to invest approximately RMB 12,000 million in a medical protective gear R&D and industrialization project, which is yet to commence[174]. - The company will enhance its digital marketing capabilities and improve operational efficiency through the integration of online and offline channels in the retail market[158]. - The company is actively seeking strategic acquisition opportunities in niche markets and key technologies globally[164].

Financial Performance - Total assets increased to ¥6,357,397,507.64, up 138.17% from the previous year[18] - Net assets attributable to shareholders reached ¥3,564,436,804.63, reflecting a 162.33% increase year-over-year[18] - Operating revenue for the first three quarters was ¥8,116,660,488.11, a 531.52% increase compared to the same period last year[18] - Net profit attributable to shareholders was ¥2,097,753,320.69, representing a 2,105.56% increase year-over-year[18] - Cash flow from operating activities amounted to ¥2,673,731,914.25, a significant increase of 2,601.70% compared to the previous year[18] - Basic earnings per share increased to ¥10.53, up 2,048.98% from the previous year[18] - The weighted average return on equity rose to 85.93%, an increase of 77.70 percentage points compared to the previous year[18] - Total revenue for the period reached ¥8,116,660,488.11, a significant increase of 531.52% compared to ¥1,285,262,447.59 in the same period last year[31] - The company reported a net profit attributable to minority shareholders of ¥312,217,850.18, a substantial increase of 3387.62% compared to ¥8,952,168.26 in the same period last year[32] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 2,077,402,698.86 RMB, representing a growth of 3,072.74% year-on-year[44] Sales and Market Performance - Sales of epidemic prevention protective products reached ¥6,107,694,520, a staggering increase of 11,599.15% year-over-year[21] - Domestic sales totaled ¥2,011,000,000, up 370.03% from the previous year, with epidemic prevention products contributing ¥1,461,000,000[21] - International sales were ¥6,098,000,000, a 612.14% increase year-over-year, with epidemic prevention products accounting for ¥4,646,000,000[21] - The company expects significant growth in net profit for the year 2020 compared to 2019, but there is uncertainty regarding the continued strong sales of pandemic-related protective products[44] Assets and Liabilities - The company's total liabilities decreased by 49.41% in bonds payable to ¥162,865,466.52 from ¥321,937,822.81, due to the conversion of some convertible bonds into shares[31] - Total liabilities as of September 30, 2020, were 2,426,256,281.71 RMB, up from 1,269,566,385.93 RMB at the end of 2019[55] - Total current liabilities were CNY 525,199,598.92, with short-term borrowings at CNY 292,487,185.54[98] Research and Development - The company is focusing on enhancing its research and development capabilities to drive innovation in new technologies[30] - Research and development expenses surged by 396.48% to ¥166,626,599.77 from ¥33,561,662.85, indicating a strong focus on innovation[31] - Research and development expenses in Q3 2020 amounted to ¥93,426,497.64, up from ¥11,017,612.97 in Q3 2019, reflecting an increase of approximately 747%[64] - The company reported a rise in research and development expenses due to increased investment in R&D during the reporting period[37] Strategic Initiatives - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[30] - There were no significant mergers or acquisitions reported during this period, indicating a focus on organic growth strategies[30] - The company aims to improve shareholder value through strategic initiatives and operational efficiencies in the upcoming quarters[30] - The company completed the acquisition of a 70% stake in Suzhou Medis Medical Sports Products Co., Ltd. for a total transaction amount of RMB 10.416 million[40] - The company has also invested RMB 30 million to acquire a 60% stake in Zhejiang Stanger Sports Protective Technology Co., Ltd. to enhance its product line in the sports rehabilitation sector[43] Cash Flow and Investments - The company reported cash inflows from investment activities totaling approximately ¥666.06 million, compared to ¥148.05 million in the previous year[81] - Cash outflows from investment activities amounted to approximately ¥1.94 billion, leading to a net cash flow from investment activities of approximately -¥1.27 billion[81] - Cash inflow from financing activities was approximately ¥1.05 billion, while cash outflows totaled approximately ¥1.07 billion, resulting in a net cash flow from financing activities of -¥27.65 million[82] - The company’s cash inflow from operating activities reflects a robust operational performance amidst challenging market conditions[86] Shareholder Information - The total number of shareholders at the end of the reporting period was 37,079, with the top ten shareholders holding a significant portion of the shares[26] - Zhejiang ZhenDe Holdings Co., Ltd. held 51.47% of the shares, making it the largest shareholder[28] - The second-largest shareholder, Shen Zhenfang, owned 4.39% of the shares, while the third-largest, Fang Shixiong, held 3.64%[28]

2020 年半年度报告 公司代码：603301 公司简称：振德医疗 振德医疗用品股份有限公司 2020 年半年度报告 1 / 145 2020 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人鲁建国、主管会计工作负责人金海萍及会计机构负责人（会计主管人员）马淑燕 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司2020年中期不进行利润分配或资本公积转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 本公司已在本报告中详细描述了可能存在的相关风险，具体内容详见本报告"第四节 经营情 况的讨论 ...

2019 年年度报告 公司代码：603301 公司简称：振德医疗 振德医疗用品股份有限公司 2019 年年度报告 1 / 190 2019 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人 鲁建国 、主管会计工作负责人 金海萍 及会计机构负责人（会计主管人员） 马 淑燕 声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 2019年度利润分配及资本公积转增股本的预案：公司拟以利润分配股权登记日总股本为基数 ，向全体股东每10股派发现金股利4.30元（含税），合计分配现金股利60,200,000元（含税）， 同时以资本公积转增股本方式向全体股东每10股转增4股，剩余未分配利润结转至下年度。在利润 分配预案公布后至利润分配股权登记日期间，若公司总股本发生变动，公司拟维持每股分配比例 不变，按照利润 ...